Pharmacovigilance news
Pharmacovigilance: new funds expected from AIFA’s Board of Directors
The new AIFA Board of Directors recently announced the allocation of funds for pharmacovigilance and cybersecurity.
Pharmacovigilance news
The new AIFA Board of Directors recently announced the allocation of funds for pharmacovigilance and cybersecurity.
There are numerous events that led to the birth of pharmacovigilance. Here is its evolution from its origins to today.
AIFA has recently embarked on a process of restructuring governance to promote investments in research and development and accelerate drug approval processes.
The latest edition of SD Collection, the SafetyDrugs special with insights, updates and useful advice on pharmacovigilance is now available.
The safety database is a fundamental tool for efficient pharmacovigilance ICSR management. Here are the main advantages of using it.
The ICSR transfer outside of EU entails risks in terms of compatibility between pharmacovigilance agreements and GDPR. Here's how be compliant.
Signal Management is the process of managing safety signals in pharmacovigilance. Here's what phases it consists of and how it is performed.
Signal Validation is the activity of verifying the reliability and completeness of the information supporting a potential signal. Here's how it's done according to GVP.
Signal Detection plays a fundamental role in the constant monitoring of the safety profile of a drug. Through this analysis it is possible to promptly identify possible signals of adverse effects associated with the use of a drug. Here's what Signal Detection is and how it's done.
Here are the best features to look for understand how to choose a safety database
A safety database is a fundamental tool for complying with pharmacovigilance regulations, allowing you to save time and resources. Here it is the reasons why a safety database is convenient for pharmaceutical companies.
The two Italian National Ethics Committees for clinical trials will evaluate the study protocols of their respective competencies on a monthly basis.
Citizens can now always be updated on any shortages of medicines thanks to AIFA Medicinali.
Medicinal products, although useful for the treatment of diseases that can afflict humans, are not free from possible risks and side effects. It is, therefore, necessary to constantly supervise the relationship between the expected benefit and the possibility and the degree of risk of each drug. Pharmacovigilance deals with this activity. Here is in detail what it is.
Educational material was a topic addressed in the Pharmacovigilance session of the 61st AFI Symposium. Here's what emerged.
AIFA is ready! The Italian Medicines Agency has announced that the new Italian National Pharmacovigilance Network will be available.
One of the various aMMRs is the dissemination of educational material to doctors and patients. Here's how to manage it and who are the actors involved.
As per tradition, the AFI Symposium dedicated a session entirely aimed at pharmacovigilance. Here's what emerged.